03 Jan 2017 --- The American College of Physicians (ACP) has recommended that physicians prescribe metformin to patients with type 2 diabetes when medication is needed to improve high blood sugar, according to an evidence-based clinical practice guideline published in Annals of Internal Medicine.
It is also published that if a second oral medication is needed to improve high blood sugar, ACP recommends that physicians consider adding a sulfonylurea, thiazolidinedione, SGLT-2 inhibitor, or DPP-4 inhibitor to metformin.
The American Academy of Family Physicians has endorsed the new guideline.
“Metformin, unless contraindicated, is an effective treatment strategy because it has better effectiveness, is associated with fewer adverse effects, and is cheaper than most other oral medications,” said Nitin S. Damle, MD, MS, MACP, president. ACP.
“The escalating rates of obesity in the U.S. are increasing the incidence and prevalence of diabetes substantially. Metformin has the added benefit of being associated with weight loss.”
ACP updated its 2012 guideline on the comparative effectiveness and safety of oral medications for the treatment of type 2 diabetes because of several new studies evaluating medications for type 2 diabetes, as well as recent FDA approvals of several new medications.
“Adding a second medication to metformin may provide additional benefits,” Dr. Damle said.
“However, the increased cost may not always support the added benefit, particularly for the more expensive, newer medications. ACP recommends that clinicians and patients discuss the benefits, adverse effects, and costs of additional medications.”
Diabetes is a leading cause of death in the US, and the disease can affect other areas of the body to cause retinopathy, nephropathy, neuropathy, and coronary artery, cerebrovascular, and peripheral vascular disease complications.
Type 2 diabetes is the most common form of the disease (affecting 90 to 95 percent of persons with diabetes), and affects about 29.1 million people in the US.
ACP's guideline is based on a systematic review of randomized controlled trials and observational studies on the comparative effectiveness of oral medications for type 2 diabetes.
ACP states that its clinical practice guidelines are developed through a rigorous process based on an extensive review of the highest quality evidence available, including randomized control trials and data from observational studies.
ACP also state that it identifies gaps in evidence and direction for future research through its guidelines development process.
19 Jan 2018 –
Frutarom Industries has completed its ...
18 Jan 2018 –
The European Food and Safety Authority (EFSA) ...
16 Jan 2018 –
Calls for a ban on the sale of energy drinks to ...
15 Jan 2018 –
Bayn Europe AB has signed a joint venture ...
15 Jan 2018 –
The European Food Safety Authority (EFSA) has ...